Adaptilens, a Boston, MA-based pre-clinical biotech company, raised $17.5M in Series A funding.
The round was led by Perceptive Xontogeny Venture Funds (PXV Funds), with additional investments from Pillar VC, 380 Cap, and Accanto Partners.
The company intends to use the funds to drive the development of its accommodating intraocular lens (A-IOL), through first-in-human trials.
Led by Founder and CEO Liane Clamen, Adaptilens is a pre-clinical biotech company focused on advancing the standard of care for cataract surgery. A soft and flexible accommodating intraocular lens (A-IOL), the Adaptilens A-IOL, is a biomimetic intraocular lens that responds to the eye’s natural signal to focus, thus eliminating the need for eyeglasses or contact lenses.
Commenting on the news, Liane Clamen said: “The young, healthy, human eye is perfectly designed, and its soft, flexible lens is what allows the eye to change power for a full range of vision. Our goal is to provide the growing number of people who need cataract surgery with a biomimetic option that restores youthful vision. This funding is meaningful as it enables our exceptional team to accelerate the development of our best-in-class A-IOL“
FinSMEs
29/04/2024